CRDF
Cardiff Oncology, Inc.
Biotechnology
Market Cap$109M
5Y Perf.-69.3%
Build Your Comparison
Side-by-side financial analysisCRDF
MGNX
TGTX
FATE
Try popular comparisons:
Stock Comparison
CRDF vs MGNX vs TGTX vs FATE
Revenue, margins, valuation, and 5-year total return — side by side.
MGNX
MacroGenics, Inc.
Biotechnology
Market Cap$255M
5Y Perf.-85.8%
TGTX
TG Therapeutics, Inc.
Biotechnology
Market Cap$7.36B
5Y Perf.+154.2%
FATE
Fate Therapeutics, Inc.
Biotechnology
Market Cap$230M
5Y Perf.-94.0%
CRDF vs MGNX vs TGTX vs FATE — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot |  CRDF |  MGNX |  TGTX |  FATE |
|---|---|---|---|---|
| Industry | Biotechnology | Biotechnology | Biotechnology | Biotechnology |
| Market Cap | $109M | $255M | $7.36B | $230M |
| Revenue (TTM) | $525K | $157M | $700M | $6M |
| Net Income (TTM) | $-45M | $-70M | $462M | $-130M |
| Gross Margin | -21.5% | 69.9% | 83.0% | 53.8% |
| Operating Margin | -90.3% | -40.5% | 21.3% | -22.1% |
| Forward P/E | — | — | 35.9x | — |
| Total Debt | $832K | $107M | $261M | $78M |
| Cash & Equiv. | $17M | $57M | $79M | $47M |
CRDF vs MGNX vs TGTX vs FATE — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
CRDF
MGNX
TGTX
FATE
| Stock | Jun 20 | Jun 26 | Return |
|---|---|---|---|
| Cardiff Oncology, I… (CRDF) | 100 | 30.7 | -69.3% |
| MacroGenics, Inc. (MGNX) | 100 | 14.2 | -85.8% |
| TG Therapeutics, In… (TGTX) | 100 | 254.2 | +154.2% |
| Fate Therapeutics, … (FATE) | 100 | 6.0 | -94.0% |
Price return only. Dividends and distributions are not included.
Quick Verdict: CRDF vs MGNX vs TGTX vs FATE
Each card shows where this stock fits in a portfolio — not just who wins on paper.
Bottom line: TGTX leads in 4 of 6 categories, making it the strongest pick for growth and revenue expansion and profitability and margin quality. MacroGenics, Inc. is the stronger pick specifically for recent price momentum and sentiment. As sector peers, any of these can serve as alternatives in the same allocation.
🥇TGTX emerged as the overall leader. Track its performance:
CRDF
Cardiff Oncology, Inc.
The Specific-Use Pick
CRDF plays a supporting role in this comparison — it may shine differently against other peers.
Best for: healthcare exposure
MGNX
MacroGenics, Inc.
The Momentum Pick
MGNX is the #2 pick in this set and the best alternative if momentum is your priority.
- +134.5% vs CRDF's -58.9%
Best for: momentum
TGTX
TG Therapeutics, Inc.
The Income Pick
TGTX carries the broadest edge in this set and is the clearest fit for income & stability and growth exposure.
- Dividend streak 0 yrs, beta 0.74
- Rev growth 87.3%, EPS growth 17.5%, 3Y rev CAGR 5.0%
- 5.8% 10Y total return vs FATE's 10.7%
- Lower volatility, beta 0.74, Low D/E 40.2%, current ratio 4.10x
Best for: income & stability and growth exposure
FATE
Fate Therapeutics, Inc.
The Secondary Option
FATE lags the leaders in this set but could rank higher in a more targeted comparison.
Best for: healthcare exposure
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth |  TGTX | 87.3% revenue growth vs FATE's -51.2% |
| Quality / Margins | TGTX | 66.0% margin vs CRDF's -85.3% |
| Stability / Safety | TGTX | Beta 0.74 vs CRDF's 2.30 |
| Dividends | Tie | None of these 4 stocks pay a meaningful dividend |
| Momentum (1Y) |  MGNX | +134.5% vs CRDF's -58.9% |
| Efficiency (ROA) | TGTX | 42.8% ROA vs CRDF's -71.5%, ROIC 16.4% vs -118.9% |
CRDF vs MGNX vs TGTX vs FATE — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
FY 2020
FY 2025
FY 2025
FY 2023
CRDF vs MGNX vs TGTX vs FATE — Financial Metrics
Side-by-side numbers across 4 stocks — who leads on profitability, valuation, growth, and risk.
BEST OVERALLTGTXLAGGINGFATE
Who Leads Where
TGTX leads in 4 of 6 categories
MGNX leads 1 • CRDF leads 1 • FATE leads 0
Explore the data ↓FATEFate Therapeutics, In…
0leads
MGNXMacroGenics, Inc.
1leads
CRDFCardiff Oncology, Inc.
1leads
TGTXTG Therapeutics, Inc.
4leads
6 Total Categories
CATEGORYLEADERvs CRDFvs MGNXMETRICS WON
Income & Cash FlowRevenue, margins, and cash flow strength
TGTX6/6
Valuation MetricsMultiples, price ratios, and targets
MGNX2/3
Profitability & EfficiencyROE, ROIC, leverage, and quality scores
TGTX6/9
Total Returns1Y, 3Y, 5Y total returns with dividends
TGTX4/6
Risk & VolatilityBeta, volatility, and downside exposure
TGTX2/2
Analyst OutlookRatings, price targets, and dividends
CRDF1/1
Income & Cash Flow (Last 12 Months)
TGTX leads this category, winning 6 of 6 comparable metrics.
Income & Cash Flow (Last 12 Months)
TGTX is the larger business by revenue, generating $700M annually — 1334.0x CRDF's $525,000. TGTX is the more profitable business, keeping 66.0% of every revenue dollar as net income compared to CRDF's -85.3%. On growth, TGTX holds the edge at +69.6% YoY revenue growth, suggesting stronger near-term business momentum.
| Metric | CRDFCardiff Oncology,… | MGNXMacroGenics, Inc. | TGTXTG Therapeutics, … |  FATEFate Therapeutics… |
|---|---|---|---|---|
| RevenueTrailing 12 months | $525,000 | $157M | $700M | $6M |
| EBITDAEarnings before interest/tax | -$46M | -$57M | $150M | -$127M |
| Net IncomeAfter-tax profit | -$45M | -$70M | $462M | -$130M |
| Free Cash FlowCash after capex | -$37M | -$72M | -$14M | -$108M |
| Gross MarginGross profit ÷ Revenue | -21.5% | +69.9% | +83.0% | +53.8% |
| Operating MarginEBIT ÷ Revenue | -90.3% | -40.5% | +21.3% | -22.1% |
| Net MarginNet income ÷ Revenue | -85.3% | -44.8% | +66.0% | -20.6% |
| FCF MarginFCF ÷ Revenue | -71.4% | -45.6% | -2.0% | -17.1% |
| Rev. Growth (YoY)Latest quarter vs prior year | -62.4% | +57.5% | +69.6% | -20.3% |
| EPS Growth (YoY)Latest quarter vs prior year | +35.7% | +10.8% | +2.9% | +18.8% |
TGTX leads this category, winning 6 of 6 comparable metrics.
Valuation Metrics
MGNX leads this category, winning 2 of 3 comparable metrics.
Valuation Metrics
| Metric | CRDFCardiff Oncology,… | MGNXMacroGenics, Inc. | TGTXTG Therapeutics, … | FATEFate Therapeutics… |
|---|---|---|---|---|
| Market CapShares × price | $109M | $255M | $7.4B | $230M |
| Enterprise ValueMkt cap + debt − cash | $92M | $304M | $7.5B | $261M |
| Trailing P/EPrice ÷ TTM EPS | -2.30x | -3.40x | 17.35x | -1.71x |
| Forward P/EPrice ÷ next-FY EPS est. | — | — | 35.88x | — |
| PEG RatioP/E ÷ EPS growth rate | — | — | — | — |
| EV / EBITDAEnterprise value multiple | — | — | 61.00x | — |
| Price / SalesMarket cap ÷ Revenue | 183.32x | 1.70x | 11.94x | 34.55x |
| Price / BookPrice ÷ Book value/share | 2.34x | 4.56x | 11.97x | 1.13x |
| Price / FCFMarket cap ÷ FCF | — | — | — | — |
MGNX leads this category, winning 2 of 3 comparable metrics.
Profitability & Efficiency
TGTX leads this category, winning 6 of 9 comparable metrics.
Profitability & Efficiency
TGTX delivers a 87.4% return on equity — every $100 of shareholder capital generates $87 in annual profit, vs $-148 for MGNX. CRDF carries lower financial leverage with a 0.02x debt-to-equity ratio, signaling a more conservative balance sheet compared to MGNX's 1.92x. On the Piotroski fundamental quality scale (0–9), TGTX scores 4/9 vs FATE's 2/9, reflecting mixed financial health.
| Metric | CRDFCardiff Oncology,… | MGNXMacroGenics, Inc. | TGTXTG Therapeutics, … | FATEFate Therapeutics… |
|---|---|---|---|---|
| ROE (TTM)Return on equity | -95.5% | -147.8% | +87.4% | -58.9% |
| ROA (TTM)Return on assets | -71.5% | -28.4% | +42.8% | -39.4% |
| ROICReturn on invested capital | -118.9% | -144.1% | +16.4% | -36.5% |
| ROCEReturn on capital employed | -75.8% | -34.7% | +17.7% | -43.1% |
| Piotroski ScoreFundamental quality 0–9 | 3 | 2 | 4 | 2 |
| Debt / EquityFinancial leverage | 0.02x | 1.92x | 0.40x | 0.38x |
| Net DebtTotal debt minus cash | -$17M | $50M | $182M | $31M |
| Cash & Equiv.Liquid assets | $17M | $57M | $79M | $47M |
| Total DebtShort + long-term debt | $832,000 | $107M | $261M | $78M |
| Interest CoverageEBIT ÷ Interest expense | — | -4.78x | 5.67x | — |
TGTX leads this category, winning 6 of 9 comparable metrics.
Total Returns (Dividends Reinvested)
TGTX leads this category, winning 4 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in TGTX five years ago would be worth $12,722 today (with dividends reinvested), compared to $220 for FATE. Over the past 12 months, MGNX leads with a +134.5% total return vs CRDF's -58.9%. The 3-year compound annual growth rate (CAGR) favors TGTX at 22.4% vs FATE's -28.6% — a key indicator of consistent wealth creation.
| Metric | CRDFCardiff Oncology,… | MGNXMacroGenics, Inc. | TGTXTG Therapeutics, … | FATEFate Therapeutics… |
|---|---|---|---|---|
| YTD ReturnYear-to-date | -40.2% | +149.1% | +64.1% | +99.0% |
| 1-Year ReturnPast 12 months | -58.9% | +134.5% | +25.4% | +27.1% |
| 3-Year ReturnCumulative with dividends | -1.9% | -30.6% | +83.4% | -63.6% |
| 5-Year ReturnCumulative with dividends | -79.8% | -81.2% | +27.2% | -97.8% |
| 10-Year ReturnCumulative with dividends | -99.5% | -84.8% | +584.5% | +10.7% |
| CAGR (3Y)Annualised 3-year return | -0.6% | -11.5% | +22.4% | -28.6% |
TGTX leads this category, winning 4 of 6 comparable metrics.
Risk & Volatility
TGTX leads this category, winning 2 of 2 comparable metrics.
Risk & Volatility
TGTX is the less volatile stock with a 0.74 beta — it tends to amplify market swings less than CRDF's 2.30 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. TGTX currently trades 97.5% from its 52-week high vs CRDF's 34.9% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | CRDFCardiff Oncology,… | MGNXMacroGenics, Inc. | TGTXTG Therapeutics, … | FATEFate Therapeutics… |
|---|---|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 2.23x | 1.43x | 0.65x | 1.93x |
| 52-Week HighHighest price in past year | $4.56 | $4.64 | $49.30 | $2.88 |
| 52-Week LowLowest price in past year | $1.36 | $1.19 | $25.28 | $0.91 |
| % of 52W HighCurrent price vs 52-week peak | +34.9% | +86.4% | +97.5% | +68.4% |
| RSI (14)Momentum oscillator 0–100 | 42.1 | 49.1 | 73.8 | 44.7 |
| Avg Volume (50D)Average daily shares traded | 1.1M | 1.0M | 1.9M | 3.1M |
TGTX leads this category, winning 2 of 2 comparable metrics.
Analyst Outlook
CRDF leads this category, winning 1 of 1 comparable metric.
Analyst Outlook
Analyst consensus: CRDF as "Buy", MGNX as "Buy", TGTX as "Buy", FATE as "Buy". Consensus price targets imply 179.2% upside for FATE (target: $6) vs 13.4% for TGTX (target: $55).
| Metric | CRDFCardiff Oncology,… | MGNXMacroGenics, Inc. | TGTXTG Therapeutics, … | FATEFate Therapeutics… |
|---|---|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Buy | Buy | Buy | Buy |
| Price TargetConsensus 12-month target | $2.00 | $6.00 | $54.50 | $5.50 |
| # AnalystsCovering analysts | 14 | 22 | 13 | 31 |
| Dividend YieldAnnual dividend ÷ price | — | — | — | — |
| Dividend StreakConsecutive years of raises | 1 | — | 0 | — |
| Dividend / ShareAnnual DPS | — | — | — | — |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | 0.0% | +1.2% | 0.0% |
CRDF leads this category, winning 1 of 1 comparable metric.
Key Takeaway
TGTX leads in 4 of 6 categories (Income & Cash Flow, Profitability & Efficiency). MGNX leads in 1 (Valuation Metrics).
Best OverallTG Therapeutics, Inc. (TGTX)Leads 4 of 6 categories
Loading custom metrics...
CRDF vs MGNX vs TGTX vs FATE: Key Questions Answered
9 questions · data-driven answers · updated daily
01Is CRDF or MGNX or TGTX or FATE a better buy right now?
For growth investors, TG Therapeutics, Inc.
(TGTX) is the stronger pick with 87. 3% revenue growth year-over-year, versus -51. 2% for Fate Therapeutics, Inc. (FATE). TG Therapeutics, Inc. (TGTX) offers the better valuation at 17. 3x trailing P/E (35. 9x forward), making it the more compelling value choice. Analysts rate Cardiff Oncology, Inc. (CRDF) a "Buy" — based on 14 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which is the better long-term investment — CRDF or MGNX or TGTX or FATE?
Over the past 5 years, TG Therapeutics, Inc.
(TGTX) delivered a total return of +27. 2%, compared to -97. 8% for Fate Therapeutics, Inc. (FATE). Over 10 years, the gap is even starker: TGTX returned +605. 4% versus CRDF's -99. 5%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
03Which is safer — CRDF or MGNX or TGTX or FATE?
By beta (market sensitivity over 5 years), TG Therapeutics, Inc.
(TGTX) is the lower-risk stock at 0. 65β versus Cardiff Oncology, Inc. 's 2. 23β — meaning CRDF is approximately 243% more volatile than TGTX relative to the S&P 500. On balance sheet safety, Cardiff Oncology, Inc. (CRDF) carries a lower debt/equity ratio of 2% versus 192% for MacroGenics, Inc. — giving it more financial flexibility in a downturn.
04Which is growing faster — CRDF or MGNX or TGTX or FATE?
By revenue growth (latest reported year), TG Therapeutics, Inc.
(TGTX) is pulling ahead at 87. 3% versus -51. 2% for Fate Therapeutics, Inc. (FATE). On earnings-per-share growth, the picture is similar: TG Therapeutics, Inc. grew EPS 1747% year-over-year, compared to -10. 3% for MacroGenics, Inc.. Over a 3-year CAGR, TGTX leads at 504. 9% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
05Which has better profit margins — CRDF or MGNX or TGTX or FATE?
TG Therapeutics, Inc.
(TGTX) is the more profitable company, earning 72. 6% net margin versus -77. 3% for Cardiff Oncology, Inc. — meaning it keeps 72. 6% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: TGTX leads at 20. 0% versus -82. 6% for CRDF. At the gross margin level — before operating expenses — CRDF leads at 100. 0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
06Is CRDF or MGNX or TGTX or FATE more undervalued right now?
Analyst consensus price targets imply the most upside for FATE: 179.
2% to $5. 50.
07Which pays a better dividend — CRDF or MGNX or TGTX or FATE?
None of the stocks in this comparison currently pay a material dividend.
All are effectively zero-yield and should be held for capital appreciation rather than income.
08Is CRDF or MGNX or TGTX or FATE better for a retirement portfolio?
For long-horizon retirement investors, TG Therapeutics, Inc.
(TGTX) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 65), +605. 4% 10Y return). Cardiff Oncology, Inc. (CRDF) carries a higher beta of 2. 23 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (TGTX: +605. 4%, CRDF: -99. 5%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
09What are the main differences between CRDF and MGNX and TGTX and FATE?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
In terms of investment character: CRDF is a small-cap quality compounder stock; MGNX is a small-cap quality compounder stock; TGTX is a small-cap high-growth stock; FATE is a small-cap quality compounder stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.